Nektar Therapeutics Stock Price. Everything You Need To Know About The Nektar Therapeutics Stock!
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 216 full-time employees. The firm’s research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body’s self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.
Nektar Therapeutics Stock Price. Everything You Need To Know About The Nektar Therapeutics Stock! performance
- Employees 216
- Company HQ San Francisco
- Website https://www.nektar.com/
- NKTR Asset Type Common Stock
- NKTR Market Capitalization 268.1M
- Earnings Per Share -1.45
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
If you’re a retail investor from Malaysia, Thailand, Indonesia, or Vietnam looking to invest in the stock market, Nektar Therapeutics could be an intriguing option to consider. Known for its cutting-edge drug development and research, Nektar Therapeutics has emerged as a leading biopharmaceutical company. But how can you invest in this stock from your respective countries? To start, it’s crucial to find a reliable investment platform like Zorion, which offers access to real US stocks and pre-IPO companies. By utilizing Zorion’s investment insights and recommendations, retail investors can make well-informed decisions about investing in Nektar Therapeutics. In addition, Zorion provides invaluable resources and educational materials to help you expand your investment knowledge, ensuring you stay ahead in the market. Don’t miss out on the opportunity to invest in the promising future of Nektar Therapeutics. Join Zorion now and start growing your investment portfolio from Malaysia, Thailand, Indonesia, or Vietnam.
